Biotech and Genomics AI Infrastructure: Protein Analysis and Genome Sequencing

Biotech AI infrastructure sits at the intersection of traditional HPC and modern deep learning, creating unique GPU requirements that neither market fully addresses. Genome sequencing generates 100-600GB of raw data per human genome on Illumina NovaSeq X instruments, and the bioinformatics pipeline converts this through alignment (BWA-MEM or DRAGEN), variant calling (DeepVariant or GATK), and annotation. DeepVariant, Google's CNN-based variant caller, requires 2-4 hours per genome on an H100 GPU versus 24+ hours on a CPU cluster. A biobank processing 100,000 genomes per year needs 20-40 dedicated H100 GPUs running continuously at a compute cost of $1.5-$3 million annually.

The broader biotech GPU landscape spans six workload categories with different hardware needs. Genome alignment and variant calling are throughput-bound and favor GPUs with high memory bandwidth like H200 (4.8 TB/s) or B200 (8 TB/s). Protein structure prediction like AlphaFold3 and ESMFold are memory-bound due to the pairwise attention mechanism over protein sequences up to 2,000 residues, requiring 40-80GB of VRAM per prediction. Molecular dynamics simulations use the most GPU compute overall, with OpenMM and GROMACS scaling across 16-128 GPUs per simulation.

The DRAGEN (Dynamic Read Analysis for GENomics) platform from Illumina is the most widely deployed GPU-accelerated genome analysis pipeline in production. DRAGEN runs on custom FPGA hardware in Illumina's integrated systems, but the software stack is also available for NVIDIA GPUs. A 30x coverage human genome through the GPU-accelerated DRAGEN pipeline completes in approximately 45 minutes on an H200, including alignment, duplicate marking, base quality score recalibration, and variant calling. This is a 30x speedup over the equivalent CPU pipeline using BWA-MEM + GATK, which requires 20-24 hours on a 32-core server.

The GPU memory requirement for genome analysis is driven by the reference genome index. The GRCh38 reference with decoy sequences consumes approximately 28GB in GPU memory for the FM-index used by the aligner. Adding the variant calling model (a 30M-parameter CNN on H200) keeps total memory under 60GB, which fits comfortably on a single H200 or B200. The bottleneck is not GPU compute but PCIe bandwidth for streaming uncompressed FASTQ data from storage. A NovaSeq X run producing 6TB of raw data per flow cell requires 50-100 GB/s of storage read bandwidth to keep the GPU pipeline fed, which demands parallel filesystem storage with at least 8-16 NVMe drives.

The protein structure prediction landscape has evolved rapidly beyond AlphaFold2. AlphaFold3 introduced a diffusion-based architecture that predicts the full atomistic structure of protein complexes including ligands, nucleic acids, and post-translational modifications. ESMFold from Meta uses a language model approach that trades some accuracy for a 60x speedup, predicting a 500-residue protein in 10-15 seconds on an H100 versus 10-15 minutes for AlphaFold3. The infrastructure decision between AlphaFold3 and ESMFold depends on whether throughput or accuracy matters more for the specific drug discovery pipeline.

Memory is the binding constraint for AlphaFold3 at scale. The pairwise attention mechanism creates an O(n^2) memory footprint in the number of residues. A protein complex with 2,000 residues requires approximately 80GB of GPU memory for a single prediction. The B200 with 180GB HBM3e is the only current GPU that can run AlphaFold3 on large complexes without memory offloading. Labs like the Baker Lab at UW run 32-64 B200 GPUs in clusters processing 1,000-5,000 protein structures per day for de novo design projects. At reserved pricing of $4.00-$5.50 per B200 GPU-hour, the compute cost for a single large complex prediction is $2-$4.

CRISPR guide RNA design uses deep learning models like DeepCRISPR, CRISPRon, and CCTop to predict on-target editing efficiency and off-target binding across the 3.2 billion base pair human genome. The evaluation requires scanning the genome for potential off-target sites that differ from the guide sequence by up to 5 mismatches. A single guide design run across the whole genome requires 200-400 H100 GPU-hours, evaluating approximately 100 million potential off-target sites through a convolutional neural network that scores each site for binding probability.

The total GPU compute for CRISPR design at therapeutic scale is substantial. A clinical CRISPR program typically evaluates 500-2,000 guide candidates per target gene, each requiring a full off-target search. The infrastructure for a biotech running 5 concurrent CRISPR programs needs 32-64 GPUs dedicated to guide design, consuming 5,000-15,000 GPU-hours per month. The compute cost of $15,000-$50,000 monthly is a small fraction of the $10-50 million preclinical development cost for a single CRISPR therapy, but the turnaround time matters: a GPU cluster can screen 2,000 guides in 3-5 days, versus 3-4 weeks on CPU clusters.

Clinical trial matching using natural language processing on electronic health records is one of the fastest-growing biotech AI workloads. A trial matching system must process unstructured clinical notes, pathology reports, and genomic test results against complex inclusion and exclusion criteria for 100,000+ active clinical trials. The NLP pipeline uses a clinical BERT model fine-tuned on i2b2/VA data, running on H100 GPUs with FP8 quantization. Processing a single patient's record through 30 criteria classifiers requires approximately 500ms of GPU time, and matching 1 million patients per month against all trials requires 150-200 H100 GPU-hours.

Real-world evidence (RWE) generation uses transformer models on longitudinal patient data to simulate clinical trial outcomes. A pharmaceutical company running RWE for a Phase 2 trial candidate processes 500,000-2,000,000 patient records through a GPT-4-sized model fine-tuned on structured and unstructured EHR data. Each patient generates 2,000-5,000 tokens of clinical text, requiring 8-16 H200 GPUs running for 2-4 weeks for a full RWE analysis at a compute cost of $80,000-$250,000. This is still 10-50x cheaper than enrolling and running the equivalent Phase 2 trial, which explains why biopharma is aggressively deploying GPU infrastructure for synthetic control arms.